Pharmacopeia
Rifaximin
Core pharmacology
- Class Group
Poorly absorbed rifamycin-derived antibiotic acting primarily within the gastrointestinal lumen.
- Main Action
Reduces intestinal bacterial load and ammonia generation, helping prevent recurrent hepatic encephalopathy.
- Mechanism of action
Binds bacterial DNA-dependent RNA polymerase, inhibiting bacterial RNA synthesis; acts predominantly within the gut.
- Indications Uses
Australian Xifaxan 550 mg indication: prevention of recurrent hepatic encephalopathy when other treatments have failed or are contraindicated; often used alongside lactulose.
- Route And Dose
Oral 550 mg twice daily is the Australian labelled regimen for prevention of recurrent hepatic encephalopathy. Indications/regimens for other uses vary by jurisdiction.
- Absorption
Very low systemic absorption in healthy subjects; systemic exposure is greater in advanced hepatic impairment despite gut-selective action.
- Distribution
Predominantly intraluminal gastrointestinal activity; reported plasma protein binding approximately 67.5% in healthy subjects when measurable.
- Excretion
Almost exclusively eliminated through faeces (mostly unchanged); only a very small proportion recovered in urine.
- Adverse Effects Toxicity
Nausea, peripheral oedema and gastrointestinal symptoms; Clostridioides difficile-associated diarrhoea, serious hypersensitivity or cutaneous reactions can occur.
- Special Points
Prevents recurrent hepatic encephalopathy but is not a substitute for correcting precipitants or providing appropriate acute encephalopathy care. Monitor for interactions and higher exposure in advanced cirrhosis; avoid unsupported claims that systemic exposure is literally zero.
Source references
These October 2026 additions were reconciled against the linked sources. Refer to current local formulary guidance for clinical prescribing.